Bactrim
(Cotrimoxazole)Phase 3Small molecule
Co-trimoxazole is an antibiotic combination used to treat bacterial infections and traveler's diarrhea. It works by stopping bacteria from growing in your body.[1] Bactrim is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Bactrim is one of 54 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 3.
2
Indications
16
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
104 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Humira
NovartisPhase 3
Stelara
Johnson & JohnsonPhase 3
Velsipity
PfizerPhase 3
Jyseleca
GileadPhase 3
Skyrizi
AbbViePhase 3
Tremfya
Johnson & JohnsonPhase 3
Mounjaro
Eli LillyPhase 3
Mesalazine
FerringPhase 3
Jardiance
Boehringer IngelheimPhase 2
Bactrim
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prophylaxis4 trials
Pregnancy2 trials
Antibiotic Prophylaxis1 trial
7 more indications
Antibiotic Resistance1 trial
Methicillin-Resistant Staphylococcus Aureus Infection1 trial
CAR1 trial
Idiopathic Pulmonary Fibrosis1 trial
Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Terminated·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT01777737·3 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cotrimoxazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details